Hideo Yagita Selected Research

Interleukin-2 (IL2)

1/2017	PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy.
1/2016	Interleukin-1 is required for cancer eradication mediated by tumor-specific Th1 cells.
1/2016	Concomitant targeting of programmed death-1 (PD-1) and CD137 improves the efficacy of radiotherapy in a mouse model of human BRAFV600-mutant melanoma.
11/2015	Rational Combination of Immunotherapies with Clinical Efficacy in Mice with Advanced Cancer.
11/2014	Inflammation and lymphopenia trigger autoimmunity by suppression of IL-2-controlled regulatory T cell and increase of IL-21-mediated effector T cell expansion.
3/2013	Th2 cell-intrinsic hypo-responsiveness determines susceptibility to helminth infection.
4/2008	Interleukin 21 enhances antibody-mediated tumor rejection.
6/2005	Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer.
10/2003	Blockade of B7-H1 suppresses the development of chronic intestinal inflammation.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hideo Yagita Research Topics

Disease

153	Neoplasms (Cancer) 01/2024 - 01/2002
31	Inflammation (Inflammations) 01/2021 - 01/2004
24	Infections 01/2017 - 06/2003
20	Neoplasm Metastasis (Metastasis) 01/2021 - 02/2002
15	Melanoma (Melanoma, Malignant) 01/2024 - 04/2008
15	Colitis 01/2021 - 02/2003
15	Autoimmune Diseases (Autoimmune Disease) 01/2019 - 07/2002
13	Breast Neoplasms (Breast Cancer) 01/2020 - 12/2005
13	Necrosis 10/2018 - 01/2002
12	Graft vs Host Disease (Graft-Versus-Host Disease) 02/2016 - 07/2002
9	Allergic Conjunctivitis (Giant Papillary Conjunctivitis) 11/2014 - 10/2004
8	Reperfusion Injury 01/2021 - 08/2008
8	Asthma (Bronchial Asthma) 01/2017 - 04/2003
7	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 01/2019 - 07/2003
7	Atherosclerosis 01/2019 - 01/2007
6	Fibrosis (Cirrhosis) 10/2023 - 05/2004
6	Ischemia 01/2021 - 08/2008
6	Leukemia 01/2021 - 05/2003
6	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2019 - 05/2002
6	Lymphoma (Lymphomas) 01/2016 - 10/2002
6	Eosinophilia 07/2011 - 07/2003
5	Hypersensitivity (Allergy) 10/2022 - 07/2003
5	Arthritis (Polyarthritis) 01/2018 - 10/2002
5	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 03/2015 - 10/2003
5	Experimental Arthritis 11/2014 - 10/2002
5	Contact Dermatitis (Eczema, Contact) 11/2014 - 10/2003
5	Multiple Sclerosis 03/2014 - 03/2010
5	Chagas Disease (American Trypanosomiasis) 04/2007 - 04/2002
4	Glomerulonephritis 01/2021 - 02/2006
4	Carcinoma (Carcinomatosis) 12/2020 - 09/2004
4	Colonic Neoplasms (Colon Cancer) 01/2020 - 09/2004
4	Sepsis (Septicemia) 01/2020 - 09/2009
4	Rheumatoid Arthritis 01/2018 - 10/2002
4	Lupus Nephritis 05/2014 - 03/2002
4	Demyelinating Diseases (Demyelinating Disease) 03/2014 - 03/2010
4	Carcinogenesis 01/2014 - 04/2009
4	Hepatitis 01/2013 - 10/2004
4	Pancreatic Neoplasms (Pancreatic Cancer) 01/2011 - 04/2007
3	Esophageal Neoplasms (Esophageal Cancer) 11/2021 - 04/2005
3	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2021 - 10/2010

Drug/Important Bio-Agent (IBA)

72	LigandsIBA 01/2021 - 01/2002
47	Monoclonal AntibodiesIBA 01/2022 - 01/2002
46	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2024 - 01/2002
45	CytokinesIBA 01/2021 - 02/2002
34	AntigensIBA 01/2022 - 05/2002
26	AntibodiesIBA 01/2021 - 01/2003
19	Proteins (Proteins, Gene)FDA Link 01/2020 - 10/2002
16	TNF-Related Apoptosis-Inducing LigandIBA 01/2021 - 02/2002
15	Fas Ligand Protein (Fas Ligand)IBA 01/2017 - 02/2002
13	TNF-Related Apoptosis-Inducing Ligand ReceptorsIBA 11/2013 - 02/2004
12	VaccinesIBA 01/2021 - 08/2008
12	DNA (Deoxyribonucleic Acid)IBA 10/2019 - 06/2003
11	Interleukin-10 (Interleukin 10)IBA 01/2020 - 10/2003
10	Therapeutic UsesIBA 01/2022 - 09/2003
9	Immune Checkpoint InhibitorsIBA 01/2024 - 01/2017
9	InterferonsIBA 01/2024 - 01/2002
9	Death Domain ReceptorsIBA 11/2022 - 01/2003
9	PerforinIBA 01/2018 - 01/2002
9	Interleukin-2 (IL2)IBA 01/2017 - 10/2003
9	Messenger RNA (mRNA)IBA 04/2016 - 03/2002
9	Immunoglobulins (Immunoglobulin)IBA 05/2014 - 04/2010
8	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2024 - 12/2004
8	Peptides (Polypeptides)IBA 01/2019 - 12/2004
8	Immunoglobulin G (IgG)IBA 10/2017 - 10/2002
7	NF-kappa B (NF-kB)IBA 01/2020 - 09/2003
7	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2019 - 11/2009
7	Neutralizing AntibodiesIBA 10/2017 - 10/2004
7	alpha-galactosylceramideIBA 08/2007 - 02/2002
6	EpitopesIBA 01/2017 - 10/2004
6	MucinsIBA 12/2013 - 02/2007
6	Interleukin-4 (Interleukin 4)IBA 03/2013 - 02/2002
6	Interferon-gamma (Interferon, gamma)IBA 02/2012 - 01/2002
5	AllergensIBA 01/2021 - 04/2003
5	Interleukin-6 (Interleukin 6)IBA 01/2021 - 01/2013
5	ChemokinesIBA 10/2020 - 01/2011
5	Immunoglobulin E (IgE)IBA 03/2017 - 10/2003
5	Interleukin-12 (IL 12)IBA 11/2016 - 02/2002
5	B7-H1 AntigenIBA 04/2016 - 03/2006
5	CaspasesIBA 01/2016 - 01/2002
5	TWEAK ReceptorIBA 07/2013 - 01/2002
5	Fibroblast Growth Factors (Fibroblast Growth Factor)IBA 04/2013 - 09/2003
5	Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA 12/2012 - 07/2007
4	LipidsIBA 10/2023 - 11/2013
4	Neoplasm Antigens (Tumor Antigens)IBA 01/2022 - 03/2009
4	InterleukinsIBA 01/2021 - 05/2007
4	Programmed Cell Death 1 ReceptorIBA 01/2020 - 02/2006
4	IntegrinsIBA 01/2019 - 09/2013
4	EnzymesIBA 01/2019 - 01/2003
4	interleukin-21 (interleukin 21)IBA 11/2014 - 06/2005
4	OvalbuminIBA 11/2014 - 04/2003
4	Mucin-1 (CA 15-3 Antigen)IBA 05/2014 - 02/2008
4	Interleukin-18 (Interleukin 18)IBA 06/2012 - 02/2002
4	CarcinogensIBA 05/2011 - 01/2002
3	Denosumab FDA Link 01/2023 - 11/2014
3	Blocking AntibodiesIBA 01/2021 - 06/2003

Therapy/Procedure

62	Therapeutics 01/2024 - 11/2002
51	Immunotherapy 10/2022 - 04/2002
11	Drug Therapy (Chemotherapy) 01/2020 - 01/2006
9	Ligation 01/2020 - 05/2003
5	Radiotherapy 01/2017 - 07/2012